Gilead

Empowering advocates for better care.

1,000,000Impressions

Organic and paid social media activity by Gilead’s official channels and its employees generated more than one million impressions.

Gilead’s Public Affairs – Oncology Advocacy was looking for ways to engage with leading breast cancer advocates.

A relatively new entrant into the oncology arena, Gilead needed to make a statement to the community that communicated the company’s credentials and genuine commitment to building a world-class oncology portfolio informed by the voices of patients.

87%Of Attendees

reported a deeper understanding of Gilead’s commitment to breast cancer.

83%Of Attendees

said they gained new insights in Gilead’s cross-functional teams and their priorities.

01Strategy

CLYDE, the Advocacy team, and their internal cross-functional partners worked together to build a new, signature touchpoint to foster bi-directional communication and information sharing with leading breast cancer advocates. It needed to provide advocates with opportunities to learn about Gilead’s many oncology functions while also providing those at Gilead the chance to hear what patients need most.

02Solution

The Breast Cancer Advocacy Summit (BCAS) was hosted on Gilead’s campus in Northern California in March 2023. CLYDE, Gilead’s Advocacy team, and more than 45 cross-functional Gilead partners came together to develop the event to reinforce Gilead’s commitment to the breast cancer community, deepen partnerships with these advocates, and advance their understanding of the company.

03Execution

Twenty-eight advocates representing major breast cancer patient advocate groups like the Susan G. Komen Foundation, American Cancer Soceity, Breastcancer.org, and more attended the event. The two-day summit included a keynote speech from four-time Olympian and breast cancer advocate Chaunte Lowe, remarks from Gilead leadership, a cross-functional poster presentation session, deep dives in Gilead’s oncology pipeline, and more.

More Work

Contact

We impact outcomes.
Let’s talk.